50.69
price up icon0.96%   0.48
after-market Handel nachbörslich: 52.06 1.37 +2.70%
loading
Schlusskurs vom Vortag:
$50.21
Offen:
$50.23
24-Stunden-Volumen:
1.21M
Relative Volume:
1.18
Marktkapitalisierung:
$3.49B
Einnahmen:
$45.48M
Nettoeinkommen (Verlust:
$169.95M
KGV:
19.35
EPS:
2.62
Netto-Cashflow:
$230.85M
1W Leistung:
-6.89%
1M Leistung:
+1.08%
6M Leistung:
+30.04%
1J Leistung:
+46.55%
1-Tages-Spanne:
Value
$49.86
$52.02
1-Wochen-Bereich:
Value
$49.86
$57.23
52-Wochen-Spanne:
Value
$32.50
$60.60

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name
Firmenname
Protagonist Therapeutics Inc
Name
Telefon
(510) 474-0170
Name
Adresse
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Name
Mitarbeiter
124
Name
Twitter
Name
Nächster Verdiensttermin
2025-05-02
Name
Neueste SEC-Einreichungen
Name
PTGX's Discussions on Twitter

Vergleichen Sie PTGX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PTGX
Protagonist Therapeutics Inc
50.69 3.49B 45.48M 169.95M 230.85M 2.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-06 Eingeleitet BMO Capital Markets Outperform
2024-12-06 Eingeleitet Goldman Neutral
2024-11-05 Eingeleitet Wedbush Outperform
2024-09-24 Eingeleitet TD Cowen Buy
2024-09-09 Eingeleitet Truist Buy
2023-10-30 Eingeleitet CapitalOne Overweight
2023-05-25 Fortgesetzt Jefferies Buy
2022-08-25 Eingeleitet JMP Securities Mkt Outperform
2022-02-11 Eingeleitet BTIG Research Buy
2021-10-12 Hochstufung JP Morgan Neutral → Overweight
2021-10-11 Hochstufung Northland Capital Market Perform → Outperform
2021-09-20 Herabstufung JP Morgan Overweight → Neutral
2021-05-24 Eingeleitet JMP Securities Mkt Outperform
2021-05-24 Eingeleitet Northland Capital Outperform
2021-01-06 Eingeleitet JP Morgan Overweight
2020-12-16 Eingeleitet Piper Sandler Overweight
2020-09-18 Bestätigt H.C. Wainwright Buy
2020-07-15 Eingeleitet Jefferies Buy
2020-05-18 Bestätigt H.C. Wainwright Buy
2019-07-08 Eingeleitet H.C. Wainwright Buy
2019-05-09 Hochstufung Stifel Hold → Buy
2018-12-06 Eingeleitet Nomura Buy
2018-01-29 Eingeleitet Stifel Buy
2017-07-21 Eingeleitet BTIG Research Buy
Alle ansehen

Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten

pulisher
Jun 18, 2025

10 Biotech Stocks Screaming a Buy - Insider Monkey

Jun 18, 2025
pulisher
Jun 18, 2025

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth By Investing.com - Investing.com South Africa

Jun 18, 2025
pulisher
Jun 18, 2025

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth - Investing.com

Jun 18, 2025
pulisher
Jun 17, 2025

BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Protagonist Therapeutics Inc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citigroup Initiates Coverage on Protagonist Therapeutics (PTGX) with a 'Buy' Rating | PTGX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $7 - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $72 Target | PTGX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

How To Trade (PTGX) - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

GAMMA Investing LLC Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Jun 16, 2025
pulisher
Jun 14, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Sells $570,300.00 in Stock - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com Canada

Jun 14, 2025
pulisher
Jun 14, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

Subdued Growth No Barrier To Protagonist Therapeutics, Inc. (NASDAQ:PTGX) With Shares Advancing 27% - simplywall.st

Jun 13, 2025
pulisher
Jun 11, 2025

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 - The Columbus Dispatch

Jun 11, 2025
pulisher
Jun 11, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Rating Increased to Hold at Wall Street Zen - MarketBeat

Jun 11, 2025
pulisher
Jun 10, 2025

Hennion & Walsh Asset Management Inc. Has $1.26 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Jun 10, 2025
pulisher
Jun 09, 2025

California State Teachers Retirement System Sells 316 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to “Hold” at Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Protagonist Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PTGX - Benzinga

Jun 06, 2025
pulisher
Jun 05, 2025

Exploring Three High Growth Tech Stocks In The US Market - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

(PTGX) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 04, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Cut to "Sell" at Wall Street Zen - MarketBeat

Jun 04, 2025
pulisher
Jun 04, 2025

Protagonist Therapeutics’ (PTGX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Protagonist-Takeda, Novartis post phase III wins - BioWorld MedTech

Jun 03, 2025
pulisher
Jun 03, 2025

H.C. Wainwright reaffirms Buy rating on Protagonist Therapeutics stock By Investing.com - Investing.com UK

Jun 03, 2025
pulisher
Jun 03, 2025

BTIG maintains buy rating on Protagonist Therapeutics stock By Investing.com - Investing.com UK

Jun 03, 2025
pulisher
Jun 03, 2025

Protagonist Therapeutics (PTGX) Rating and Price Target Reaffirmed | PTGX Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 02, 2025

Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

ASCO 2025: Protagonist-Takeda, Novartis post phase III wins - BioWorld MedTech

Jun 02, 2025
pulisher
Jun 02, 2025

Transcript : Protagonist Therapeutics, Inc.Special Call - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Protagonist Therapeutics (PTGX): Promising Phase 3 Results for R - GuruFocus

Jun 02, 2025
pulisher
Jun 01, 2025

Protagonist Therapeutics (PTGX): Promising Phase 3 Results for Rusfertide | PTGX Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera - Quantisnow

Jun 01, 2025
pulisher
May 31, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Downgraded to Sell Rating by Wall Street Zen - Defense World

May 31, 2025
pulisher
May 29, 2025

Cache Advisors LLC Makes New $392,000 Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

May 29, 2025
pulisher
May 28, 2025

Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome - MSN

May 28, 2025
pulisher
May 28, 2025

D. E. Shaw & Co. Inc. Sells 21,121 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

May 28, 2025
pulisher
May 28, 2025

Bank of America Corp DE Has $5.21 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

May 28, 2025
pulisher
May 27, 2025

Protagonist Therapeutics’ SWOT analysis: stock poised for growth amid clinical advancements - Investing.com India

May 27, 2025
pulisher
May 25, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Reduced by Ameriprise Financial Inc. - Defense World

May 25, 2025
pulisher
May 24, 2025

Protagonist Therapeutics' (PTGX) Buy Rating Reiterated at HC Wainwright - MarketBeat

May 24, 2025
pulisher
May 23, 2025

BNP Paribas Financial Markets Has $751,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

May 23, 2025
pulisher
May 23, 2025

Protagonist Therapeutics earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada

May 23, 2025
pulisher
May 21, 2025

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 | PTGX Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Exclusive: Protagonist Therapeutics CEO Reveals Company Strategy at Major Jefferies Healthcare Conference - Stock Titan

May 21, 2025
pulisher
May 20, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of “Buy” from Analysts - Defense World

May 20, 2025
pulisher
May 20, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Given “Buy” Rating at HC Wainwright - Defense World

May 20, 2025

Finanzdaten der Protagonist Therapeutics Inc-Aktie (PTGX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Protagonist Therapeutics Inc-Aktie (PTGX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
MOLINA ARTURO MD
Chief Medical Officer
Jun 10 '25
Option Exercise
8.04
10,000
80,400
93,892
MOLINA ARTURO MD
Chief Medical Officer
Jun 10 '25
Sale
57.03
10,000
570,300
83,892
MOLINA ARTURO MD
Chief Medical Officer
Jun 09 '25
Sale
55.51
10,000
555,100
83,892
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):